Patients developing metastatic castration-resistant prostate cancer are in most instances pre-treated with androgen deprivation treatment and a newer androgen receptor-targeting agent in the metastatic castration-sensitive setting.
In this article, I discuss the first- and second-line treatment options in this patient population.
(BELG J MED ONCOL 2023;17(1):15–8)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
